Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units
Infections with multidrug-resistant organisms among patients in intensive care units (ICUs) are associated with high mortality. Among multidrug-resistant organisms, carbapenem-resistant Enterobacterales (CRE) harbor important pathogens for healthcare-associated infections, including pneumonia, bacteremia, and urinary tract infections. Risk factors for CRE colonization include underlying comorbid conditions, prior antibiotics exposure, prior use of healthcare facilities, device use, and longer ICU stay. The mortality rate due to invasive CRE infection is 22%-49%, and CRE colonization is associated with an approximately 10-fold increased risk of CRE infection. Infection control measures include hand hygiene, contact precautions, minimizing the use of devices, and environmental control. Additionally, implementing active surveillance of CRE carriage should be considered in ICU settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Acute and critical care - 36(2021), 3 vom: 10. Aug., Seite 175-184 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yi, Jongyoun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Carbapenem |
|---|
| Anmerkungen: |
Date Revised 21.09.2021 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.4266/acc.2021.00409 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329240870 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329240870 | ||
| 003 | DE-627 | ||
| 005 | 20231225204704.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4266/acc.2021.00409 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1097.xml |
| 035 | |a (DE-627)NLM329240870 | ||
| 035 | |a (NLM)34380190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yi, Jongyoun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Infections with multidrug-resistant organisms among patients in intensive care units (ICUs) are associated with high mortality. Among multidrug-resistant organisms, carbapenem-resistant Enterobacterales (CRE) harbor important pathogens for healthcare-associated infections, including pneumonia, bacteremia, and urinary tract infections. Risk factors for CRE colonization include underlying comorbid conditions, prior antibiotics exposure, prior use of healthcare facilities, device use, and longer ICU stay. The mortality rate due to invasive CRE infection is 22%-49%, and CRE colonization is associated with an approximately 10-fold increased risk of CRE infection. Infection control measures include hand hygiene, contact precautions, minimizing the use of devices, and environmental control. Additionally, implementing active surveillance of CRE carriage should be considered in ICU settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a carbapenem | |
| 650 | 4 | |a carbapenem-resistant enterobacteriaceae | |
| 650 | 4 | |a drug resistance | |
| 650 | 4 | |a infection control | |
| 650 | 4 | |a intensive care units | |
| 700 | 1 | |a Kim, Kye-Hyung |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acute and critical care |d 2018 |g 36(2021), 3 vom: 10. Aug., Seite 175-184 |w (DE-627)NLM303272988 |x 2586-6060 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2021 |g number:3 |g day:10 |g month:08 |g pages:175-184 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4266/acc.2021.00409 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2021 |e 3 |b 10 |c 08 |h 175-184 | ||